XML 13 R4.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Product sales, net $ 1,853,764 $ 2,909,966 $ 4,102,609 $ 5,507,564
Cost of products sold 442,560 1,019,907 1,015,302 1,728,882
Gross profit 1,411,204 1,890,059 3,087,307 3,778,682
Selling, general and administrative expenses 2,868,182 3,937,281 5,903,458 7,011,012
Research and development expenses 314,968 213,647 409,179 353,994
Depreciation and amortization expense 8,477 16,681 20,161 33,902
Total operating expenses 3,191,627 4,167,609 6,332,798 7,398,908
Loss from operations (1,780,423) (2,277,550) (3,245,491) (3,620,226)
Interest income (expense) 20,966 48,722 45,505 72,067
Gain on sale of net operating losses 1,983,095 0 1,983,095 0
Loss before provision for income taxes 223,638 (2,228,828) (1,216,891) (3,548,159)
Net income (loss) 223,638 (2,228,828) (1,216,891) (3,548,159)
Net (loss) attributable to noncontrolling interests 0 (12,511) 0 (24,176)
Net income (loss) attributable to Milestone Scientific Inc. $ 223,638 $ (2,216,317) $ (1,216,891) $ (3,523,983)
Net income (loss) per share applicable to common stockholders—        
Basic and Diluted (in dollars per share) $ 0 $ (0.03) $ (0.02) $ (0.05)
Weighted average shares outstanding and to be issued—        
Basic (in shares) 79,966,833 72,333,656 80,412,397 72,048,223
Diluted (in shares) 79,967,086 72,333,656 80,412,397 72,048,223